Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade
This study demonstrated that the modified and more stable TLR2 agonist SUP3 provided an optimal strategy for promoting antitumor immunity via activation of cDC1. SUP3 enhanced antigen cross-presentation by cDC1 and subsequent activation of CTLs. The antitumor effect was further enhanced when SUP3 and Flt3L synergized with PD-L1 blockade. Therefore, reactivation of suppressed DCs in tumor microenvironment would be a promising strategy for designing effective antitumor immunotherapy.
Authors
- Xueheng Guo (ORCID: https://orcid.org/0000-0002-9396-9296)
- Xuebin Liao (ORCID: https://orcid.org/0000-0002-0290-894X)
- Zhenkang Ai (ORCID: https://orcid.org/0009-0007-1382-5959)
- Tao Wu (ORCID: https://orcid.org/0000-0001-9347-5723)
- Xin Liu (ORCID: https://orcid.org/0000-0002-6634-4012)
- Di Wang (ORCID: https://orcid.org/0000-0002-6221-0949)
- Chao Wang (ORCID: https://orcid.org/0000-0001-9760-1846)
- Yuanhao Wang (ORCID: https://orcid.org/0000-0002-9384-5445)
- Zhisong Wang (ORCID: https://orcid.org/0000-0002-2264-2990)
- Li Wu (ORCID: https://orcid.org/0000-0002-2802-1220)
- Maocai Luo (ORCID: https://orcid.org/0000-0002-5624-9572)
- Qingqing Sun
- Jiaoyan Lv
Institutions
- King Center (US)
- Beijing Meteorological Bureau (CN)
- Center for Life Sciences (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1186/s13046-025-03571-9
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- National Natural Science Foundation of China
- Tsinghua University